Athersys, Inc.

ATHX | $0.1018 -40.86% 95M

(0.0% 1d) (0.0% 1m) (-87.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
Sec Filling | Patents | 83 employees

(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

cardiovascular stem cell urea t-cell neurological ceiling

add to watch list Paper trade email alert is off

MESOBLAST LTD

MEOBF | $0.1667 314.16% 10K

Health Technology

(0.0% 1d) (0.0% 1m) (-72.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (900.0% volume)
Earnings Calendar:
Market Cap: $ 215,452,372
http://www.mesoblast.com
Sec Filling | Patents | n/a employees

(AU) Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

t-cell stem cell ceiling cardiovascular

add to watch list Paper trade email alert is off

Brainstorm Cell Therapeutics Inc.

BCLI A | $0.5339 1.7% 1.67% 190K

Health Technology

(0.0% 1d) (-16.7% 1m) (-80.4% 1y) (0.0% 2d) (3.8% 3d) (3.8% 7d) (18.99% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 36,487,717
http://www.brainstorm-cell.com
Sec Filling | Patents | 32 employees

(US) Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

sclerosis stem cell spinal cord multiple sclerosis t-cell parkinson bone msa nurown treatment ceiling

add to watch list Paper trade email alert is off

BioLife Solutions, Inc.

BLFS S | $17.165 0.85% 0.84% 520K

Health Technology

(0.0% 1d) (-5.0% 1m) (-4.4% 1y) (0.0% 2d) (1.0% 3d) (8.4% 7d) (-0.91% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 777,574,500
http://www.biolifesolutions.com
Sec Filling | Patents | 158 employees

BioLife Solutions, Inc. engages in the development, manufacture and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

stem cell t-cell ceiling

add to watch list Paper trade email alert is off

Histogen Inc.

HSTO | $0.35 67.46% 5.4K

Health Technology

(0.0% 1d) (-12.5% 1m) (-61.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (29.61% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 1,495,116
http://www.histogen.com
Sec Filling | Patents | 6 employees

Histogen, Inc. engages in the development of patented, innovative technologies that replace and regenerate tissues in the body for the aesthetic and therapeutic markets. Its technology is based on the discovery that growing fibroblast cells under simulated embryonic conditions induces them to become multipotent stem cells. The environment created by its proprietary process mimics the conditions within the womb very low oxygen and suspension. When cultured under these conditions, the induced multipotent stem cells generate biological materials that stimulate a patient’s own stem cells to activate and regenerate tissue. This results in potential therapeutic benefits in multiple treatment settings, including skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers. The company was founded on July 13, 2005 by Steven J. Mento and is headquartered in San Diego, CA.

dermatitis cartilage skin stem cell t-cell aesthetic treatment ceiling

add to watch list Paper trade email alert is off

Immunome, Inc.

IMNM | $14.28 -2.59% -2.66% 560K

Health Technology

(0.0% 1d) (-43.8% 1m) (169.2% 1y) (0.0% 2d) (-2.7% 3d) (-7.8% 7d) (-37.72% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 852,433,790
http://www.immunome.com
Sec Filling | Patents | 21 employees

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

cancer stem cell antibody t-cell msa ceiling

add to watch list Paper trade email alert is off

Lineage Cell Therapeutics, Inc.

LCTX | $1.1 -3.51% 0.0% 740K

Health Technology

(0.0% 1d) (-16.0% 1m) (-18.5% 1y) (0.0% 2d) (-3.5% 3d) (-4.3% 7d) (124.28% volume)
Earnings Calendar:
Market Cap: $ 207,386,890
http://www.lineagecell.com
Sec Filling | Patents | 55 employees

(US) Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

hydrogen cancer stem cell t-cell drug delivery diagnostics neurological 3d msa ceiling

add to watch list Paper trade email alert is off

Mesoblast Limited

MESO | $6.21 3.5% 3.38% 200K

Health Technology

(0.0% 1d) (129.5% 1m) (-74.5% 1y) (0.0% 2d) (3.7% 3d) (19.4% 7d) (-68.39% volume)
Earnings Calendar:
Market Cap: $ 708,381,997
http://www.mesoblast.com
Sec Filling | Patents | 102 employees

(AU) Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

cardiovascular stem cell t-cell ceiling

add to watch list Paper trade email alert is off

ThermoGenesis Holdings, Inc.

THMO | $0.69 9.47% 7.7K

Health Technology

(0.0% 1d) (-7.0% 1m) (-66.0% 1y) (0.0% 2d) (-5.8% 3d) (-1.5% 7d) (69.7% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 5,487,418
http://www.thermogenesis.com
Sec Filling | Patents | 50 employees

(US) ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing. The Clinical Development segment utilizes autologous stem cell-based therpeutics. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

gene therapies stem cell t-cell ceiling

add to watch list Paper trade email alert is off